We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

111 hedge funds and large institutions have $67.2M invested in Sanofi Contingent Value Rights in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more capital invested

Capital invested by funds: $58.1M → $67.2M (+$9.1M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

8% less funds holding

Funds holding: 120111 (-9)

33% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 12

36% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 22

Holders
111
Holders Change
-9
Holders Change %
-7.5%
% of All Funds
2.76%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
14
Reduced
22
Closed
12
Calls
Puts
Net Calls
Net Calls Change

GCVRZ Hedge Fund Activity: Q1 2017 in Review

111 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2017, worth a combined $67.2M — up 16% from $58.1M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of GCVRZ and 8 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 14 added.

The largest buyer was Stonehill Capital Management, adding an estimated $588K. The largest seller was Whitebox Advisors, cutting an estimated $1.76M.

  • 111 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2017, down from 120 in Q4 2016.
  • Funds reported $67.2M of Sanofi Contingent Value Rights stock for Q1 2017, up 16% quarter-over-quarter.
  • 8 funds opened new Sanofi Contingent Value Rights positions in Q1 2017 and 12 closed out, a net change of -4 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q1 2017 was Stonehill Capital Management, an estimated $588K added.
  • The largest Sanofi Contingent Value Rights seller in Q1 2017 was Whitebox Advisors, an estimated $1.76M sold.

Based on aggregated 13F filings for Q1 2017.